- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsing-remitting multiple sclerosis (RRMS)
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meeting - (PDF 901KB)
- Public Summary Document (PSD) November 2023 PBAC Meeting - (Word 61KB)
Cladribine – November 2023
Cladribine: Tablet 10 mg; Mavenclad®
Last updated
15 March 2024